Related Experiment Video
Updated: Aug 22, 2025
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.5K
Metalloproteinases and Tissue Inhibitors in Generalized Myasthenia Gravis. A Preliminary Study
Vincenzo Di Stefano1, Chiara Tubiolo1, Andrea Gagliardo1
1Department of Biomedicine, Neuroscience and Advanced Diagnostic (BIND), University of Palermo, 90127 Palermo, Italy.
Brain Sciences
|November 11, 2022
Summary
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) show altered levels in generalized myasthenia gravis (MG). These biomarkers may indicate disease severity and risk of clinical deterioration in MG patients.
Area of Science:
- Biochemistry
- Immunology
- Neurology
Background:
- Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are implicated in immune-mediated disorders.
- Their role in generalized myasthenia gravis (MG) requires further investigation.
Purpose of the Study:
- To evaluate plasma levels of MMP-9, MMP-2, TIMP-1, and TIMP-2 in generalized MG patients.
- To assess the correlation between these biomarkers and disease severity in MG.
Main Methods:
- Plasma concentrations of MMP-9, MMP-2, TIMP-1, and TIMP-2 were measured in 14 generalized MG patients and 13 healthy controls.
- Disease severity was assessed using the modified Osserman classification.
Main Results:
- MG patients exhibited increased MMP-9 and decreased MMP-2 and TIMP-1 plasma levels compared to controls.
- Elevated MMP-2 levels correlated positively with increased disease severity.
- MMP-9/TIMP-1 ratio increased, while MMP-2/TIMP-2 ratio decreased in MG patients.
Conclusions:
- MMPs and TIMPs may play a role in the pathogenesis of generalized MG.
- These biomarkers could be associated with the risk of clinical deterioration in MG patients.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
01:15Myasthenia Gravis: Diagnostic Tests
1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K
01:26Chemical Synapses
9.0K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.0K
01:28Disorders of the Skeletal Muscle
1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
01:10Muscle Contraction
6.7K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.7K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
750
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
750